Astrana Health, Inc.

Astrana Health, Inc.(ASTH)股票分析

$37.960

-0.444 (-1.17%)收盘时

Loading chart…
High
38.680
Open
38.460
VWAP
38.10
Vol
368.70K
Mkt Cap
Low
37.660
Amount
14.05M
EV/EBITDA, TTM
10.64

Astrana Health, Inc. is a physician-centric, artificial intelligence (AI)-powered healthcare company focused on delivering patient-centered care. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company's segments include Care Partners, Care Delivery, and Care Enablement. Its Care Partners segment is focused on building and managing provider networks by partnering with, empowering, and investing in provider partners aligned on a shared vision for coordinated care delivery. Its Care Delivery organization includes primary care, multi-specialty care, and ancillary care services. Its Care Enablement segment represents a comprehensive platform that integrates clinical, operational, financial, and administrative information. It supports more than 20,000 providers.

AI analysis of Astrana Health, Inc. (ASTH)

buy

Astrana Health Inc is a good buy right now due to its impressive revenue growth of 55.4% over the past two years and a current price of $37.96, which is significantly lower than the average analyst price target of $55. This suggests substantial upside potential. Additionally, the company has shown a positive trend in earnings with an EPS of $0.40 reported in Q2, exceeding estimates by 29.03%. However, the RSI is at 45.75, indicating it is nearing oversold territory, which could present a risk if momentum does not improve.

估值指标

The current forward P/E ratio for Astrana Health, Inc. (ASTH) is 23.04, compared to its 5-year average forward P/E of 35.95.

Forward P/E

Fair
5Y Average P/E
35.95
Current P/E
23.04
高估
54.56
低估
17.35

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
11.49
Current EV/EBITDA
10.64
高估
17.19
低估
5.79

Forward P/S

Fair
5Y Average P/S
1.09
Current P/S
0.43
高估
2.02
低估
0.15

Alphio AI Price Scenarios for ASTH

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ASTH

$46.65

情景价格

B

Base

Base · 50%ASTH

$38.04

情景价格

B

Bear

Bear · 25%ASTH

$34.25

情景价格

Whales holding ASTH

S

SteelPeak Wealth, LLC

+ HoldingASTH

-3.05%

3M Return

事件时间线

2026-05-11 (ET)

16:30:00

Astrana Health Partners with PAC to Empower Independent Physicians

2026-05-07 (ET)

16:20:00

Sees Q2 Adjusted EBITDA of $65M-$70M

16:20:00

Sees FY26 Adjusted EBITDA of $250M to $280M

16:20:00

Astrana Health Q1 Revenue $965.1M Beats Expectations

2026-03-31 (ET)

06:20:00

Astrana Health Files Automatic Mixed Securities Shelf

资讯

ASTH FAQ — answered by Alphio AI

Astrana Health, Inc. is a physician-centric, artificial intelligence (AI)-powered healthcare company focused on delivering patient-centered care. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company's segments include Care Partners, Care Delivery, and Care Enablement. Its Care Partners segment is focused on building and managing provider networks by partnering with, empowering, and investing in provider partners aligned on a shared vision for coordinated care delivery. Its Care Delivery organization includes primary care, multi-specialty care, and ancillary care services. Its Care Enablement segment represents a comprehensive platform that integrates clinical, operational, financial, and administrative information. It supports more than 20,000 providers. It operates in the Healthcare sector (MANAGEMENT CONSULTING SERVICES industry).

Astrana Health Inc is a good buy right now due to its impressive revenue growth of 55.4% over the past two years and a current price of $37.96, which is significantly lower than the average analyst price target of $55. This suggests substantial upside potential. Additionally, the company has shown a positive trend in earnings with an EPS of $0.40 reported in Q2, exceeding estimates by 29.03%. However, the RSI is at 45.75, indicating it is nearing oversold territory, which could present a risk if momentum does not improve.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始